IGF1R and melanoma: Because there are no FDA-approved/brain penetrant IGF1R inhibitors, we used ceritinib, a noncanonical drug against IGF1R as proof of principle and noted its effectiveness against melanoma cells in this LMD model with acquired resistance to MAPK inhibitors (as occurs clinically).